In line with these findings, our multi-stage risk classifier combines inexpensive routine blood markers (DHEA-S, androstenedione, SHBG, etc.)with clinical variables (PSAD, DRE findings, prostate volume) to assess which patients are most likely to have aggressive PC. This evidence concerns the gene SHBG and pachyonychia congenita.